Clopidogrel resistance: Fact and fiction

Future Cardiology

Volumn 2, Issue 2, 2006, Pages 215-228

  van Werkum, J W ^a   Heestermans, A A C M ^a   Deneer, V H M ^a   Hackeng, C M ^a   ten Berg, J M ^a  

^a ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

Antiplatelet therapy; Clopidogrel resistance; Post treatment platelet reactivity

Indexed keywords

3 [7 [2 (3,4 DIFLUOROPHENYL)CYCLOPROPYLAMINO] 5 PROPYLTHIO 1,2,3 TRIAZOLO[4,5 D]PYRIMIDIN 3 YL] 5 HYDROXYMETHOXY 1,2 CYCLOPENTANEDIOL; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CANGRELOR; CLOPIDOGREL; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; FIBRIN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; PRASUGREL; PURINE P2Y12 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; SIMVASTATIN; THROMBIN; UNCLASSIFIED DRUG; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ACUTE CORONARY SYNDROME; ARTERY THROMBOSIS; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG METABOLISM; DRUG RESEARCH; DRUG RESISTANCE; DRUG RESPONSE; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HEMOSTASIS; HUMAN; INTESTINE ABSORPTION; METHODOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; REVIEW; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOGENESIS; THROMBOSIS;

EID: 33646559855     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/14796678.2.2.215     Document Type: Review

References (113)

1. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345(7), 494-502 (2001).
2. Steinhubl SR, Berger PB, Mann JT 3rd et al.: CREDO Investigators: clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288(19), 2411-2420 (2002).
3. Jaremo P, Lindahl TL, Fransson SG, Richter A: Individual variations of platelet inhibition after loading doses of clopidogrel. J. Intern. Med. 252(3), 233-238 (2002).
4. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM: Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107(23), 2908-2913 (2003).
5. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ: Variability in platelet responsiveness to clopidogrel among 544 individuals. J. Am. Coll. Cardiol. 45(2), 246-251 (2005).
6. Gurbel PA, Bliden KP: Durability of platelet inhibition by clopidogrel. Am. J. Cardiol. 91(9), 1123-1125 (2003).
7. Angiolillo, DJ, Fernandez-Ortiz A, Bernardo E et al.: Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb. Res. 115(1-2), 101-108 (2005).
8. Azuma H, Ishikawa M, Sekizaki S: Endothelium-dependent inhibition of platelet aggregation. Br. J. Pharmacol. 88(2), 411-415 (1986).
9. Radomski MW, Palmer RMJ, Moncada S: The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br. J. Pharmacol. 92, 639-646 (1987).
10. Michelson AD, Benoit SE, Furman MI et al.: Effects of nitric oxide/EDRF on platelet surface glycoproteins. Am. J. Physiol. 270(5 Pt 2), H1640-H1648 (1996).
11. Sugimoto M, Tsuji S, Kuwahara M et al.: Shear-dependent functions of the interaction between soluble von Willebrand factor and platelet glycoprotein Ib in mural thrombus formation on a collagen surface. Int. J. Hematol. 69(1), 48-53 (1999).
12. Wu YP, Vink T, Schiphorst M et al.: Platelet thrombus formation on collagen at high shear rates is mediated by von Willebrand factor-glycoprotein Ib interaction and inhibited by von Willebrand factor-glycoprotein IIb/IIIa interaction. Arterioscler. Thromb. Vasc. Biol. 20(6), 1661-1667 (2000).
13. Nurden AT, Nurden P: A review of the role of platelet membrane glycoproteins in the platelet-vessel wall interaction. Baillieres Clin. Haematol. 6(3), 653-690 (1993).
14. Yuan Y, Dopheide SM, Ivanidis C, Salem HH, Jackson SP: Calpain regulation of cytoskeletal signaling complexes in von Willebrand factor-stimulated platelets. Distinct roles for glycoprotein Ib-V-IX and glycoprotein IIb-IIIa (integrin αIIbβ3) in von Willebrand factor-induced signal transduction. J. Biol. Chem. 272 (35), 21847-21854 (1997).
15. Savage B, Shattil SJ, Ruggeri ZM: Modulation of platelet function through adhesion receptors. A dual role for glycoprotein IIb-IIIa (integrin αIIbβ3) mediated by fibrinogen and glycoprotein Ib-von Willebrand factor. J. Biol. Chem. 267(16), 11300-11306 (1992).
16. Andrews RK, Shen Y, Gardiner EE, Berndt MC: Platelet adhesion receptors and (patho)physiological thrombus formation. Histol. Histopathol. 16(3), 969-980 (2001).
17. Arya M, Lopez JA, Romo GM et al.: Glycoprotein Ib-IX-mediated activation of integrin alpha(IIb)beta(3): effects of receptor clustering and von Willebrand factor adhesion. J. Thromb. Haemost. 1(6), 1150-1157 (2003).
18. Andrews RK, Berndt MC: Platelet physiology and thrombosis. Thromb. Res. 114(5-6), 447-453 (2004).
19. Pereillo JM, Maftouh M, Andrieu A et al.: Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab. Dispos. 30(11), 1288-1295 (2002).
20. Savi P, Pereillo JM, Uzabiaga J et al.: Identification and biological activity of the active metabolite of clopidogrel. Thromb. Haemost. 84, 891-896 (2000).
21. Reist M, Vos MR-D, Montseny J-P et al.: Very slow chiral conversion of clopidogrel in rats: a pharmacokinetic and mechanistic investigation. Drug Metab. Dispos. 28, 1405-1410 (2000).
22. Savi P, Combalbert J, Gaich C et al.: The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb. Haemost. 72, 313-317 (1994).
23. Arrebola MM, De la Cruz JP, Villalobos MA, Pinacho A, Guerrero A, Sanchez de la Cuesta F: In vitro effects of clopidogrel on the platelet-subendothelium interaction, platelet thromboxane and endothelial prostacyclin production, and nitric oxide synthesis. J. Cardiovasc. Pharmacol. 43(1), 74-82 (2004).
24. Daniel JL, Dangelmaier C, Jin J, Ashby B, Smith JB, Kunapuli SP: Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J. Biol. Chem. 273, 2024-2029 (1998).
25. Jin J, Daniel JL, Kunapuli SP: Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J. Biol. Chem. 273, 2030-2034 (1998).
26. Leon C, Hechler B. Freund M et al.: Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptornull mice. J. Clin. Invest. 104, 1731-1737 (1999).
27. Cattaneo M, Zighetti ML, Lombardi R et al.: Molecular bases of defective signal transduction in platelet P2Y12 receptor of a patient with congenital bleeding. Proc. Natl Acad. Sci. USA 100, 1978-1983 (2003).
28. Baurand A, Eckly A, Bari N et al.: Desensitization of the platelet aggregation response to ADP: differential down-regulation of the P2Y1 and P2cyc-receptor. Thromb. Haemost. 84, 484-491 (2000).
29. Hardy AR, Conley PB, Luo J, Benovic JL, Poole AW, Mundell SJ: P2Y1 and P2Y12 receptors for ADP desensitize by distinct kinase-dependent mechanisms. Blood 105, 3552-3560 (2005).
30. Muller I, Besta F, Schulz C, Massberg S, Schomig A, Gawaz M: Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb. Haemost. 89(5), 783-787 (2003).
31. Mobley JE, Bresee SJ, Wortham DC, Craft RM, Snider CC, Carroll RC: Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization. Am. J. Cardiol. 93(4), 456-458 (2004).
32. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al.: Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? J. Invasive Cardiol. 16(4), 169-174 (2004).
33. Angiolillo, DJ, Fernandez-Ortiz A, Bernardo E et al.: High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur. Heart J. 25(21), 1903-1910 (2004).
34. Soffer D, Moussa I, Harjai K et al.: Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina? Catheter Cardiovasc. Interv. 59, 21-25 (2003).
35. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al.: Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention. Am. J. Cardiol. 97(1). 38-43 (2006).
36. Nguyen TA, Diodati JG, Pharand C: Resistance to clopidogrel: a review of the evidence. J. Am. Coll. Cardiol. 45(8), 1157-1164 (2005).
37. Wiviott SD, Antman EM: Clopidogrel resistance: a new chapter in a fast-moving story. Circulation 109(25), 3064-3067 (2004).
38. Refaal MA, Laposata M: Platelet aggregation. In: Platelets. Michelson AD (Ed.). Academic Press, San Diego, CA, USA, 291-296 (2004).
39. Born GV, Dearnley R. Foulks JG, Sharp DE: Quantification of the morphological reaction of platelets to aggregating agents and of its reversal by aggregation inhibitors. J. Physiol. 280, 193-212 (1978).
40. Riess H, Braun G, Brehm G, Hiller E: Critical evaluation of platelet aggregation in whole human blood. Am. J. Clin. Pathol. 85(1), 50-6 (1986).
41. Michelson AD: Platelet function testing in cardiovascular diseases. Circulation 110(19), e489-e493 (2004).
42. George JN: Platelets. Lancet 355, 1531-1539 (2000).
43. Nicholson NS, Panzer-Knodle SG, Haas NF et al.: Assessment of platelet function assays. Am. Heart J. 135(5 Pt 2 Su), S170-S178 (1998).
44. Breddin HK: Can platelet aggregometry be standardized? Platelets 16(3-4), 151-158 (2005).
45. Mani H, Luxembourg B, Klaffling C, Erbe M, Lindhoff-Last E: Use of native or platelet count adjusted platelet rich plasma for platelet aggregation measurements. J. Clin. Pathol. 58(7), 747-750 (2005).
46. 2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 96(5), 1488-1494 (1997).
47. Labarthe B, Theroux P, Angioi M, Ghitescu M: Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. J. Am. Coll. Cardiol. 46(4), 638-645 (2005).
48. Patel P, Gonzales R, Dokainish H, Lakkis N: Impact of adenosine diphosphate and calcium chelation on platelet aggregation testing in patients receiving clopidogrel therapy. J. Am. Coll. Cardiol. 47(2), 464-465 (2006).
49. Mammen EF, Comp PC, Gosselin R et al.: PFA-100 system: a new method for assessment of platelet dysfunction. Semin. Thromb. Hemost. 24, 195-202 (1998).
50. Favaloro EJ: Clinical application of the PFA-100(R). Curr. Opin. Hematol. 9(5), 407-415 (2002).
51. Kottke-Marchant K, Powers JB, Brooks L, Kundu S, Christie DJ: The effect of antiplatelet drugs, heparin, and preanalytical variables on platelet function detected by the platelet function analyzer (PFA 100). Clin. Appl. Thromb. Hemost. 5, 122-130 (1999).
52. Hezard N, Metz D, Nazeyrollas P, Droulle C, Potron G, Nguyen P: PFA-100 and flow cytometry: can they challenge aggregometry to assess antiplatelet agents, other than GPIIbIIIa blockers, in coronary angioplasty? Thromb. Res. 108(1), 43-47 (2002).
53. Golanski J, Pluta J, Baraniak J, Watala C: Limited usefulness of the PFA-100 for the monitoring of ADP receptor antagonists - in vitro experience. Clin. Chem. Lab. Med. 42(1), 25-29 (2004).
54. Smith JW, Steinhubl SR, Lincoff AM et al.: Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation 99(5), 620-625 (1999).
55. Von Beckerath N, Pogatsa-Murray G, Wieczorek A, Schömig A, Kastrati A: Correlation between platelet response units measured with a point-of-care test and ADP-induced platelet aggregation assessed with conventional aggregometry. Eur. Soc. Cardiol. Congr. Stockholm, Sweden, 3-7 September 2005, (Abstract P2936).
56. Craft RM, Chavez JJ, Snider CC, Muenchen RA, Carroll RC: Comparison of modified thrombelastograph and plateletworks whole blood assays to optical aggregation for monitoring reversal of clopidogrel inhibition in elective surgery patients. J. Lab. Clin. Med. 145(6), 309-315 (2005).
57. Soffer D, Taviloglu G, New G et al.: What is the appropriate loading dose of clopidogrel prior to stent implantation? Insights from a platelet inhibition study. J. Am. Coll. Cardiol. 35(Suppl. A) (2000).
58. Lau WC, Bates ER, Carville DGM et al.: Rapid platelet function assessment using two concentrations of adenosine diphosphate after clopidogrel loading dose in patients undergoing cardiac catheterization. J. Am. Coll. Cardiol. 35(Suppl. A) (2000).
59. Rivard GE, Brummel-Ziedins KE, Mann KG, Fan L, Hofer A, Cohen E: Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thromboelastography. J. Thromb. Haemost. 3, 2039-2043 (2005).
60. Khurana S, Mattson JC, Westley S, O'Neill WW, Timmis GC, Safian RD: Monitoring platelet glycoprotein IIb/IIIa-fibrin interaction with tissue factor-activated thromboelastography. J. Lab. Clin. Med. 130, 401-411 (1997).
61. McCrath D, Cerboni E, Hirsh A, Frumento RJ, Bennet-Guerrero E: Association of thrombelastography (MA) and thrombotic complications after major non-cardiac surgery, Anesth. Analag. 96, SCA1-SCA141 (2003).
62. Gurbel PA, Bliden KP Guyer K et al.: Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J. Am. Coll. Cardiol. 46(10), 1820-1826 (2005).
63. Shenkman B, Savion N, Dardik R, Tamarin I, Varon D: Testing of platelet deposition on polystyrene surface under flow conditions by the cone and plate(let) analyzer: role of platelet activation, fibrinogen, and von Willebrand factor. Thromb. Res. 99, 353-361 (2000).
64. Spectre G, Brill A, Gural A et al.: A new point-of-care method for monitoring anti-platelet therapy: application of the cone and plate(let) analyzer. Platelets 16(5), 293-299 (2005).
65. Matetzky S, Shenkman B, Guetta V et al.: Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109(25), 3171-3175 (2004).
66. Aleil B, Meyer N, Cazenave JP, Mossard JM, Gachet C: High stability of blood samples for flow cytometric analysis of VASP phosphorylation to measure the clopidogrel responsiveness in patients with coronary artery disease. Thromb. Haemost. 94(4), 886-887 (2005).
67. Geiger J, Teichmann L, Grossmann R et al: Monitoring of clopidogrel action: comparison of methods. Clin. Chem. 51(6), 957-965 (2005).
68. Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C: Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J. Thromb. Haemost. 3(1), 85-92 (2005).
69. Barragan P, Bouvier JL, Roquebert PO et al.: Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc. Interv. 59(3), 295-302 (2003).
70. Schwarz UR, Geiger J, Walter U, Eigenthaler M: Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets - definition and detection of ticlopidine/clopidogrel effects. Thromb. Haemost. 82(3), 1145-1152 (1999).
71. Hochholzer W, Trenk D, Fischer B et al.: Impact of peri-interventional platelet inhibition after loading with clopidogrel on 30-days clinical outcome of elective coronary stent placement: the Excelsior Study Eur. Soc. Cardiol. Congr. Stockholm, Sweden, 3-7 September 2005, (Abstract 2230).
72. Cuisset T, Frere C, Quilici J et al.: High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J. Thromb. Haemost. (2005) (Epub ahead of print).
73. Caplain H, Donat F, Gaud C, Necciari J: Pharmacokinetics of clopidogrel. Semin. Thromb. Hemost. 25(Suppl. 2), 25-28 (1999).
74. Savcic M, Hauert J, Bachmann F: Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic responses in healthy subjects. Semin. Thromb. Haemost. 25, 15-19 (1999).
75. Muller I, Seyfarth M, Rudiger S et al.: Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 85(1), 92-93 (2001).
76. Kastrati A, von Beckerath N, Joost A, Pogatsa-Murray G, Gorchakova O, Schomig A: Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation 110(14), 1916-1919 (2004).
77. Montalescot G, on behalf of all Albion study investigators: Assessment of the best loading dose of clopidogrel to blunt platelet activation, inflammation and ongoing necrosis: the Albion study. Eur. Soc. Cardiol. Congr. Stockholm, Sweden, 3-7 September 2005, (Abstract 2956).
78. von Beckerath N, Taubert D, Pogatsa-Murray G, Schomig E, Kastrati A, Schomig A: Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 112(19), 2946-2950 (2005).
79. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G: Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 111(16), 2099-2106 (2005).
80. Taubert D, Kastrati A, Harlfinger S et al.: Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb. Haemost. 92(2), 311-316 (2004).
81. Wojnowski L: Genetics of the variable expression of CYP3A in humans. Ther. Drug Monit. 26(2), 192-199 (2004).
82. Clarke TA, Waskell LA: The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab. Dispos. 31(1), 53-59 (2003).
83. Hustert E, Haberl M, Burk O et al.: The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11(9), 773-779 (2001).
84. Lamba JK, Lin YS, Schuetz EG, Thummel KE: Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev. 54(10), 1271-1294 (2002).
85. Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR: Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5(3), 243-272 (2004).
86. Angiolillo DJ, Bernardo E, Ramirez C et al.: Pharmacogenetic modulation of clopidogrel antiplatelet effects: role of gene sequence variations of the CYP3A4 enzyme. Eur. Soc. Cardiol. Congr. Stockholm, Sweden, 3-7 September 2005, (Abstract P3510).
87. Lau WC, Waskell LA, Watkins PB et al.: Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 107, 32-37 (2003).
88. Neubauer H, Gunesdogan B, Hanefeld C, Spiecker M, Mugge A: Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function - a flow cytometry study. Eur. Heart J. 24(19), 1744-1749 (2003).
89. Saw J, Steinhubl SR. Berger PB et al.: Clopidogrel for the reduction of events during observation investigators: lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 108(8), 921-924 (2003).
90. Serebruany VL, Midei MG, Malinin AI et al.: Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. Arch. Intern. Med. 164(18), 2051-2057 (2004).
91. Serebruany VL, Steinhubl SR, Hennekens CH: Are antiplatelet effects of clopidogrel inhibited by atorvastatin? A research question formulated but not yet adequately tested. Circulation 107(12), 1568-1569 (2003).
92. Schror K, Weber AA, Hohlfeld T: Clopidogrel 'resistance' and statin cotreatment - significant for cardiocoronary prevention in real life? Thromb. Haemost. 94(2), 235-237 (2005).
93. Hochholzer W, Trenk D, Frundi D et al.: No impact of statins metabolised by CYP3A4 on the antiplatelet effect and the clinical outcome after a 600 mg loading dose of clopidogrel in patients undergoing elective coronary angiography: Eur. Soc. Cardiol. Congr. Stockholm, Sweden, 3-7 September 2005, (Abstract 2952).
94. Fontana P, Dupont A, Gandrille S et al.: Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subject. Circulation 108, 989-995 (2003).
95. Fontana P, Gaussems P, Aiach M, Fiessinger JN, Emmerich J, Reny JL: P2Y12 H2 haplotype is associated with peripheral artery disease: a case-control study. Circulation 108, 2971-2973 (2003).
96. Angiolillo D, Fernandez-Ortiz A, Bernardo E et al.: Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thromb. Res. (2005).
97. Angiolillo DJ, Bernardo E, Ramirez C et al.: P2Y12 receptor polymorphism and clopidogrel response: is there a link? Eur. Soc. Cardiol. Congr 3-7 September 2005, Stockholm, Sweden (Abstract P3514).
98. von Beckerath N, von Beckerath O, Koch W, Eichinger M, Schomig A, Kastrati A: P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. Blood Coagul. Fibrinolysis 16(3), 199-204 (2005).
99. Gurbel PA, Samara WM, Bliden KP: Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis. Platelets 15, 95-99 (2004).
100. Gawaz M, Neumann FJ, Ott I, Schiessler A, Schömig A: Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 93(2), 229-237 (1996).
101. Gurbel PA, Samara WM, Bliden KP: Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis. Platelets 15, 95-99 (2004).
102. Tantry US, Bliden KP, Hayes K, Yoho J, Gurbel PA: Overestimation of platelet aspirin resistance. J. Am. Coll. Cardiol. 45, 427A (2005).
103. Farb A, Burke AP, Kolodgie FD, Virmani R: Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation 108(14), 1701-1706 (2003).
104. Hong MK, Mintz GS, Lee CW et al.: Incidence, mechanism, predictors, and long-term prognosis of late stent malapposition after bare-metal stent implantation. Circulation 109(7), 881-886 (2004).
105. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al.: Platelet function profiles in patients with Type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54(8), 2430-2435 (2005).
106. Watala C: Blood platelet reactivity and its pharmacological modulation in (people with) diabetes mellitus. Curr. Pharm. Des. 11(18), 2331-2365 (2005).
107. Sobel BE, Schneider DJ: Platelet function, coagulopathy, and impaired fibrinolysis in diabetes. Cardiol. Clin. 22(4), 511-526 (2004).
108. Watala C, Golanski J, Pluta J et al.: Reduced sensitivity of platelets from Type 2 diabetic patients to acetylsalicylic acid (aspirin) - its relation to metabolic control. Thromb. Res. 113(2), 101-113 (2004).
109. Brandt JT, Payne CD, Weerakkody G et al.: Superior responder rate for inhibition of platelet aggregation with a 60 mg loading dose of prasugrel (CS-747, LY640315) compared with a 300 mg loading dose of clopidogrel. J. Am. Coll. Cardiol. 45(Suppl. 1), 87A (2005).
110. Asai F, Jakubowski JA, Winters KJ et al.: A comparison of prasugrel (CS-747, LY640315) with clopidogrel on platelet function in healthy male volunteers. J. Am. Coll. Cardiol. 45(Suppl. 1), 87A (2005).
111. 12 receptor antagonist, compared with clopidogrel in aspirin-treated patients with atherosclerotic vascular disease. J. Am. Coll. Cardiol. 45(Suppl. 1), 416A (2005).
112. Husted S, Emanuelsson H, Heptinstall S, Clark S, Peters G: Greater and less variable inhibition of platelet aggregation (IPA) with AZD6140, the first oral reversible ADP receptor antagonist, compared with clopidogrel in patients with atherosclerosis. Eur. Soc. Cardiol. Congr. Stockholm, Sweden, 3-7 September 2005, (Abstract 3764).
113. 12 antagonists. Semin. Thromb. Hemost. 31, 195-204 (2005).